Consistently, genotyping analyses of patients treated with 5-FU and irinotecan within the randomized phase III Nordic IV trial[126] and the randomized phase III TRIBE trial[127], confirmed the association between the UGT1A1*28/*28 genotype and higher risk of neutropenia. Here, UGT1A1 is linked to neutropenia.